Annual SG&A
$7.16 M
-$1.25 M-14.84%
01 December 2023
Summary:
TransCode Therapeutics annual selling, general & administrative expenses is currently $7.16 million, with the most recent change of -$1.25 million (-14.84%) on 01 December 2023. During the last 3 years, it has risen by +$3.76 million (+110.61%). RNAZ annual SG&A is now -14.84% below its all-time high of $8.40 million, reached on 31 December 2022.RNAZ Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$938.00 K
-$1.09 M-53.85%
01 September 2024
Summary:
TransCode Therapeutics quarterly selling, general & administrative expenses is currently $938.00 thousand, with the most recent change of -$1.09 million (-53.85%) on 01 September 2024. Over the past year, it has increased by +$204.00 thousand (+27.79%). RNAZ quarterly SG&A is now -66.60% below its all-time high of $2.81 million, reached on 31 December 2022.RNAZ Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$208.35 M
-$14.93 M-7.72%
01 September 2024
Summary:
TransCode Therapeutics TTM selling, general & administrative expenses is currently -$208.35 million, with the most recent change of -$14.93 million (-7.72%) on 01 September 2024. Over the past year, it has dropped by -$215.50 million (-3011.93%). RNAZ TTM SG&A is now -5918.34% below its all-time high of $9.23 million, reached on 01 September 2023.RNAZ TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RNAZ Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +27.8% | -3011.9% |
| 3 y3 years | +110.6% | -44.9% | -6233.0% |
| 5 y5 years | +3002.8% | - | - |
RNAZ Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -14.8% | +110.6% | -66.6% | +27.8% | -573.5% | at low |
| 5 y | 5 years | -14.8% | +3002.8% | -66.6% | +7228.1% | -5918.3% | at low |
| alltime | all time | -14.8% | +3002.8% | -66.6% | +7228.1% | -5918.3% | at low |
TransCode Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $938.00 K(-53.8%) | $5.23 M(-16.4%) |
| June 2024 | - | $2.03 M(+32.8%) | $6.26 M(-2.0%) |
| Mar 2024 | - | $1.53 M(+108.4%) | $6.39 M(-10.7%) |
| Dec 2023 | $7.16 M(-14.8%) | $734.00 K(-62.7%) | $7.16 M(-22.5%) |
| Sept 2023 | - | $1.97 M(-8.8%) | $9.23 M(+0.6%) |
| June 2023 | - | $2.16 M(-6.1%) | $9.17 M(+0.8%) |
| Mar 2023 | - | $2.30 M(-18.2%) | $9.10 M(+8.3%) |
| Dec 2022 | $8.40 M | $2.81 M(+47.1%) | $8.40 M(+15.2%) |
| Sept 2022 | - | $1.91 M(-8.5%) | $7.29 M(+8.0%) |
| June 2022 | - | $2.09 M(+30.8%) | $6.75 M(+40.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $1.60 M(-6.2%) | $4.81 M(+41.5%) |
| Dec 2021 | $3.40 M(+668.4%) | $1.70 M(+24.4%) | $3.40 M(+76.6%) |
| Sept 2021 | - | $1.37 M(+850.6%) | $1.92 M(+159.2%) |
| June 2021 | - | $143.80 K(-22.6%) | $742.30 K(+20.7%) |
| Mar 2021 | - | $185.70 K(-18.3%) | $615.10 K(+39.1%) |
| Dec 2020 | $442.10 K(+91.7%) | - | - |
| Dec 2020 | - | $227.20 K(+22.4%) | $442.20 K(+105.7%) |
| Sept 2020 | - | $185.60 K(+1018.1%) | $215.00 K(+631.3%) |
| June 2020 | - | $16.60 K(+29.7%) | $29.40 K(+129.7%) |
| Mar 2020 | - | $12.80 K | $12.80 K |
| Dec 2019 | $230.60 K | - | - |
FAQ
- What is TransCode Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for TransCode Therapeutics?
- What is TransCode Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for TransCode Therapeutics?
- What is TransCode Therapeutics quarterly SG&A year-on-year change?
- What is TransCode Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for TransCode Therapeutics?
- What is TransCode Therapeutics TTM SG&A year-on-year change?
What is TransCode Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of RNAZ is $7.16 M
What is the all time high annual SG&A for TransCode Therapeutics?
TransCode Therapeutics all-time high annual selling, general & administrative expenses is $8.40 M
What is TransCode Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of RNAZ is $938.00 K
What is the all time high quarterly SG&A for TransCode Therapeutics?
TransCode Therapeutics all-time high quarterly selling, general & administrative expenses is $2.81 M
What is TransCode Therapeutics quarterly SG&A year-on-year change?
Over the past year, RNAZ quarterly selling, general & administrative expenses has changed by +$204.00 K (+27.79%)
What is TransCode Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of RNAZ is -$208.35 M
What is the all time high TTM SG&A for TransCode Therapeutics?
TransCode Therapeutics all-time high TTM selling, general & administrative expenses is $9.23 M
What is TransCode Therapeutics TTM SG&A year-on-year change?
Over the past year, RNAZ TTM selling, general & administrative expenses has changed by -$215.50 M (-3011.93%)